Associated Genetic Biomarkers
High mobility group AT-hook 2 (HMGA2) is a gene that encodes a protein that functions as an architectural factor and a component of the enhancesome. The protein may also be a transcriptional regulator. Fusions, missense mutations, silent mutations, and nonstop extensions are observed in cancers such as breast cancer, liver cancer, and lung cancer.
HMGA2 is altered in 0.06% of all cancers.
HMGA2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains HMGA2 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with HMGA2 status in the inclusion eligibility criteria most commonly target breast carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is HMGA2 Overexpression .
Bintrafusp alfa is the most frequent therapy in trials with HMGA2 as an inclusion criteria .
Significance of HMGA2 in Diseases
Breast Carcinoma +
HMGA2 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HMGA2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.